Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
CHEO Genetics Diagnostic Laboratory, |
RCV001170303 | SCV001332872 | likely pathogenic | Familial thoracic aortic aneurysm and aortic dissection | 2017-11-08 | criteria provided, single submitter | clinical testing | |
Centre of Medical Genetics, |
RCV000663895 | SCV002025412 | likely pathogenic | Marfan syndrome | 2021-03-01 | criteria provided, single submitter | research | PM2, PS7, PP4 |
Labcorp Genetics |
RCV001861733 | SCV002238218 | pathogenic | Marfan syndrome; Familial thoracic aortic aneurysm and aortic dissection | 2020-12-10 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant has been observed in individual(s) with Marfan syndrome (PMID: 19293843). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 549363). This variant is not present in population databases (ExAC no frequency). This sequence change affects an acceptor splice site in intron 55 of the FBN1 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in FBN1 are known to be pathogenic (PMID: 17657824, 19293843). |
Center for Medical Genetics Ghent, |
RCV000663895 | SCV000787261 | likely pathogenic | Marfan syndrome | 2017-11-07 | no assertion criteria provided | clinical testing |